INOVIQ (ASX:IIQ), formerly BARD1 Life Sciences Ltd (ASX:BD1), is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. INOVIQ has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

Latest Media Releases

INOVIQ - Ovarian Cancer Test Validation

19/04/2024 08:41:00

INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85…

Latest News